Ipsen: positive preliminary data for Cabometyx

(CercleFinance.com) - Ipsen has announced positive results from the pivotal phase III "CheckMate -9ER" trial evaluating its Cabometyx (cabozantinib) in combination with Bristol Myers' Opdivo (nivolumab) in previously untreated advanced renal cell carcinoma (RCC).


The combination has achieved its primary endpoint of significantly improving progression-free survival on final analysis, as well as the secondary endpoints (overall survival and objective response rate) on the planned interim analysis.

The tolerance profiles of Cabometyx and Opdivo observed in this study are comparable to the known tolerance profiles of the immunotherapy components and the tyrosine kinase inhibitor for first-line treatment of RCC.


Copyright (c) 2020 CercleFinance.com. All rights reserved.